Dasatinib: a leukaemia drug used three days at a time, and why that is not a small thing

This is the senolytic with actual human trial data, and it is also a cancer drug with a real adverse-effect profile. Both facts belong in the same sentence, and most writing about it keeps them apart.

What it is before it is a senolytic

Established clinical use Dasatinib is a tyrosine kinase inhibitor approved for chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia. It inhibits BCR-ABL and a broad range of other kinases including the SRC family, and that breadth is both why it works in leukaemia and why it has the side-effect profile it does. Pleural effusion, myelosuppression, bleeding risk and QT prolongation are all recognised effects at treatment doses.

Off-label or community practice Its senolytic identity came out of a screen: senescent cells resist apoptosis by upregulating specific survival pathways, and dasatinib was one of the compounds found to disable them. The proposed use is nothing like the leukaemia use — two or three days every few months rather than continuously — and the argument is that a brief exposure is enough to kill cells whose defences it disables while being too short for the cumulative toxicity that daily treatment produces.

That argument is plausible and it is not the same as demonstrated. Total exposure is genuinely far lower. Whether it is low enough to avoid the effects that matter is something the trials were not powered to establish.

What the human trials actually measured

Established clinical use Dasatinib combined with quercetin is the most studied senolytic protocol in people, and the trials are small, open-label and endpoint-modest. In diabetic kidney disease, a short course reduced senescent cell burden in adipose tissue and skin — measured directly, which is the strongest thing anyone has shown for a senolytic in humans. In idiopathic pulmonary fibrosis, an open-label pilot reported improvement in some physical function measures.

What has not been shown is a change in a hard clinical outcome, in any trial, in any indication. Reduced senescent cell burden is a mechanistic confirmation, not a benefit. The distance between "the drug does the thing it was supposed to do" and "people are better off" is exactly where this field currently sits, and it is the honest summary.

The fisetin page covers the supplement alternative, which has mouse data and no human outcome trial. Neither is established. This one at least has been measured in people.

Why this one is not a self-directed decision

Dasatinib requires a prescription and the app’s own entry says physician oversight is absolutely required, which is unusually emphatic for this reference and is correct. Three specifics make it so. It has a broad and clinically significant interaction profile through CYP3A4, so the full medication list matters. It suppresses blood counts, which is why the app puts a full blood count before and two weeks after each pulse on the monitoring list. And bleeding risk means anticoagulants and antiplatelet drugs are a genuine concern rather than a theoretical one.

Off-label or community practice Nobody has established what the cumulative risk of a pulse protocol repeated over years looks like, because nobody has run it for years. That is not a reason to assume harm; it is a reason to describe this as an experimental protocol being taken outside a trial, which is what it is.

The trial protocols this is copied from ran under monitoring, with stopping rules and scheduled bloodwork. Reproducing the dose without reproducing the monitoring is taking the risk without the safeguards, and that is the specific thing to avoid here. Anything on the drawbacks list below is a conversation with a prescriber, not a page.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Dasatinib, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app’s own entry. The first item is not boilerplate on this compound — it is the one that separates it from everything else in the senolytic category.

• Prescription drug — physician oversight absolutely required
• Side effects at cancer doses are significant — longevity doses are much lower
• Not FDA approved for longevity or anti-aging
• Drug interactions — check all current medications
• Bone marrow suppression monitoring required
• Cost — brand name expensive, generic available

Questions people actually ask

Is it safe at senolytic doses?

Total exposure is far lower than in leukaemia treatment, and the short trials reported it as tolerated. What nobody has established is the cumulative risk of repeating a pulse protocol over years, because that has not been run.

What did the trials actually show?

Directly measured reduction in senescent cell burden in tissue, which is the strongest mechanistic confirmation any senolytic has in people, and some physical-function signals in a small open-label pilot. No hard clinical outcome in any trial.

Why is it paired with quercetin?

Because the two disable different survival pathways, and senescent cells in different tissues depend on different ones. The pairing is what the trial protocols used, and it is why the combination rather than either alone is what has human data.

What monitoring does a pulse need?

A full blood count before and about two weeks after, because it suppresses counts, plus liver enzymes and a review of every other medication for CYP3A4 interactions. That is the app’s own panel and it is not optional.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.